Ignite Creation Date:
2024-05-05 @ 11:35 PM
Last Modification Date:
2024-10-26 @ 10:35 AM
Study NCT ID:
NCT01360437
Status:
COMPLETED
Last Update Posted:
2012-06-22
First Post:
2011-05-23
Brief Title:
Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention
Sponsor:
University of Patras
Organization:
University of Patras
Study Overview
Official Title:
Ticagrelor in Comparison to Prasugrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndrome ACS Presenting Resistance to the Usual Clopidogrel Dose After PCI
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-center randomized single-blind investigator-initiated pharmacological study with a crossover design Patients with acute coronary syndrome ST-elevation myocardial infarction non-ST elevation myocardial infarction unstable angina and presenting high on-clopidogrel platelet reactivity as assessed with the VerifyNow assay platelet reactivity units PRU235 24 hours post percutaneous coronary intervention PCI will be randomized after informed consent in a 11 ratio to either prasugrel 10mgd or ticagrelor 90mg twice a day for 15 days Platelet reactivity assessment will be performed at Day 152 days and then a crossover directly to the alternate treatment group for an additional 15 days period without an intervening washout period will be carried out Patients will return at Day 302 days for platelet reactivity assessment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None